Neuronoff is a medical device company developing a neuromodulation platform designed to lower the barrier to peripheral nerve stimulation therapies. The company’s core technology, the Injectrode®, aims to transform traditional implanted neuromodulation procedures into a simpler, needle-based outpatient intervention.

The Injectrode platform uses an injectable or needle-delivered electrode approach to create an electrical interface near target nerves without the surgical burden of conventional lead implantation. The system is designed to support both trial and longer-term therapy pathways, enabling patients to try neuromodulation earlier in the pain treatment timeline with simplified placement and removability.

Neuronoff’s initial focus is chronic pain, positioning the platform for use in clinical pain management and interventional care settings. The company also describes broader applicability of the same minimally invasive neuromodulation approach across additional peripheral nerve targets and organ-related indications.